DERM Cash-Secured Put Strategy
DERM (Journey Medical Corporation), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
DERM (Journey Medical Corporation) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $141.9M, a beta of 1.04 versus the broader market, a 52-week range of 4.31-9.555, average daily share volume of 226K, a public-listing history dating back to 2021, approximately 41 full-time employees. These structural characteristics shape how DERM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.04 places DERM roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a cash-secured put on DERM?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current DERM snapshot
As of May 15, 2026, spot at $6.25, ATM IV 312.00%, IV rank 63.37%, expected move 89.45%. The cash-secured put on DERM below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this cash-secured put structure on DERM specifically: DERM IV at 312.00% is mid-range versus its 1-year history, so the credit collected on a DERM cash-secured put sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 89.45% (roughly $5.59 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DERM expiries trade a higher absolute premium for lower per-day decay. Position sizing on DERM should anchor to the underlying notional of $6.25 per share and to the trader's directional view on DERM stock.
DERM cash-secured put setup
The DERM cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DERM near $6.25, the first option leg uses a $5.94 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DERM chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DERM shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $5.94 | N/A |
DERM cash-secured put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
DERM cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on DERM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use cash-secured put on DERM
Cash-secured puts on DERM earn premium while a trader waits to acquire DERM stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning DERM.
DERM thesis for this cash-secured put
The market-implied 1-standard-deviation range for DERM extends from approximately $0.66 on the downside to $11.84 on the upside. A DERM cash-secured put lets a trader earn premium while waiting to acquire DERM at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current DERM IV rank near 63.37% is mid-range against its 1-year distribution, so the IV signal is neutral; the cash-secured put thesis on DERM should anchor more to the directional view and the expected-move geometry. As a Healthcare name, DERM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DERM-specific events.
DERM cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DERM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DERM alongside the broader basket even when DERM-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on DERM carry tail risk when realized volatility exceeds the implied move; review historical DERM earnings reactions and macro stress periods before sizing. Always rebuild the position from current DERM chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on DERM?
- A cash-secured put on DERM is the cash-secured put strategy applied to DERM (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With DERM stock trading near $6.25, the strikes shown on this page are snapped to the nearest listed DERM chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are DERM cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the DERM cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 312.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a DERM cash-secured put?
- The breakeven for the DERM cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current DERM market-implied 1-standard-deviation expected move is approximately 89.45%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on DERM?
- Cash-secured puts on DERM earn premium while a trader waits to acquire DERM stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning DERM.
- How does current DERM implied volatility affect this cash-secured put?
- DERM ATM IV is at 312.00% with IV rank near 63.37%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.